Metsera company information, Employees & Contact Information

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio Business Wire

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 Yahoo Finance

Pfizer Beat Out Two Other Metsera Suitors for Takeover BioSpace

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug CNBC

Pfizer To Acquire Metsera For $4.9 Billion citybiz

Pfizer: Buy The Pharma Giant Following The Metsera Deal (NYSE:PFE) Seeking Alpha

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion The Wall Street Journal

Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet Bloomberg.com

Pfizer moves to acquire Metsera in bold re entry into obesity drug race PharmiWeb.com

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting Yahoo Finance

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera CNBC

Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition BioSpace

Metsera to Present at Upcoming September Investor Conferences Yahoo Finance

Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more CNBC

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® Yahoo Finance

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i Yahoo Finance

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress Yahoo Finance

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress Yahoo Finance

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress Yahoo Finance

Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity. renaissancecapital.com

Metsera Prices Initial Public Offering at $18 Per Share The Healthcare Technology Report.

Metsera Moves Fast in Crowded Obesity Market With IPO Plans BioSpace

MTSR Stock Price and Chart — NASDAQ:MTSR TradingView

Metsera Secures $215 Million Series B Financing citybiz

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares FinancialContent

Pfizer's new prize Metsera touts 14% weight loss, 'class-leading tolerability' for lead GLP-1 drug Fierce Biotech

Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1 BioSpace

Pfizer to buy obesity-focused Metsera in $4.9 billion deal statnews.com

Metsera strengthens case for Pfizer buyout with latest study data BioPharma Dive

Pfizer buys back into obesity drug chase with $4.9B Metsera deal BioPharma Dive

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal Investopedia

Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks Fierce Biotech

Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy (NYSE:PFE) Seeking Alpha

Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More MedCity News

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. Barron's

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs South China Morning Post

Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet The Business of Fashion

Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal Investor's Business Daily

Pfizer bets $7.3 billion on obesity drugs with Metsera buy Fast Company

Metsera Stock Jumps 60%. Pfizer Is Jumping Back Into the Weight-Loss Race. Barron's

Pfizer Near Potential $7.3 Billion Metsera Takeover, FT Says Bloomberg.com

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases Business Wire

Metsera posts weight loss data for amylin analog, teeing up monthly GLP-1 combo plans Fierce Biotech

Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR) Seeking Alpha

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med MedCity News

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases Business Wire

Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097 Business Wire

What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? The Motley Fool

Metsera, Maze secure combined $415 million in IPOs BioPharma Dive

Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Days BioSpace

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump Investor's Business Daily

Metsera raises $215M to accelerate obesity drug plans BioPharma Dive

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR Business Wire

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market HIT Consultant

Obesity-focused Metsera files IPO just 9 months after emerging Fierce Biotech

Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles TheStreet

Metsera eyes $289M IPO to fund phase 3 weight loss trial Fierce Biotech

Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s MedCity News

Metsera Launches with Focus on Medicines for Obesity & Metabolic Diseases Contract Pharma

Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing Fierce Biotech

High-flying Metsera follows phase 1 weight loss data with $215M series B raise Fierce Biotech

Metsera Inc. (MTSR) Zacks Investment Research

After phase 1 data drop, Metsera allies with Amneal for supply of GLP-1, amylin weight loss candidates Fierce Biotech

New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss, Few Side Effects BioSpace

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo BioPharma Dive

With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments Fierce Biotech

Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market BioSpace

Metsera Shares Rocket on Pfizer's $7.3bn Deal But Is It Too Late to Buy In? International Business Times UK

Pfizer to acquire obesity-drug maker Metsera for $4.9 bn The Guardian Nigeria News

D&D Pharmatech, Metsera expand collaboration for new obesity, MASH treatments koreabiomed.com

Pfizer nears Metsera takeover The Star